Atlas Trials

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Clinical trial NCT04134936 · COMPLETED

Trial details

NCT number
NCT04134936
Sponsor
MorphoSys AG
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2019-12-11
Primary completion
2021-02-11
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.